These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
299 related items for PubMed ID: 29253594
21. Development of a multi-epitope peptide vaccine inducing robust T cell responses against brucellosis using immunoinformatics based approaches. Saadi M, Karkhah A, Nouri HR. Infect Genet Evol; 2017 Jul; 51():227-234. PubMed ID: 28411163 [Abstract] [Full Text] [Related]
22. The Brucella melitensis M5-90ΔmanB live vaccine candidate is safer than M5-90 and confers protection against wild-type challenge in BALB/c mice. Zhang J, Yin S, Yi D, Zhang H, Li Z, Guo F, Chen C, Fang W, Wang J. Microb Pathog; 2017 Nov; 112():148-155. PubMed ID: 28916316 [Abstract] [Full Text] [Related]
26. A DNA vaccine coding for the chimera BLSOmp31 induced a better degree of protection against B. ovis and a similar degree of protection against B. melitensis than Rev.1 vaccination. Cassataro J, Pasquevich KA, Estein SM, Laplagne DA, Zwerdling A, de la Barrera S, Bowden R, Fossati CA, Giambartolomei GH, Goldbaum FA. Vaccine; 2007 Aug 10; 25(32):5958-67. PubMed ID: 17600596 [Abstract] [Full Text] [Related]
28. PLGA (85:15) nanoparticle based delivery of rL7/L12 ribosomal protein in mice protects against Brucella abortus 544 infection: A promising alternate to traditional adjuvants. Singh D, Somani VK, Aggarwal S, Bhatnagar R. Mol Immunol; 2015 Dec 10; 68(2 Pt A):272-9. PubMed ID: 26442664 [Abstract] [Full Text] [Related]
32. Efficacy evaluation of live Escherichia coli expression Brucella P39 protein combined with CpG oligodeoxynucleotides vaccine against Brucella melitensis 16M, in BALB/c mice. Al-Mariri A, Mahmoud NH, Hammoud R. Biologicals; 2012 Mar 10; 40(2):140-5. PubMed ID: 22296786 [Abstract] [Full Text] [Related]
33. [Different aluminum adjuvants significantly enhances the effect of immunization on Brucella Omp31]. Qing R, Xiang Q, Liu Z, Xiao F, Yang F. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 Feb 10; 34(2):123-128. PubMed ID: 29673454 [Abstract] [Full Text] [Related]
35. The evaluation of immunogenic impact of selected bacterial, recombinant Hsp60 antigens in DBA/2J mice. Bajzert J, Gorczykowski M, Galli J, Stefaniak T. Microb Pathog; 2018 Feb 10; 115():100-111. PubMed ID: 29246635 [Abstract] [Full Text] [Related]
36. Immunogenicity of Brucella Trivalent Immunogen-Containing Polyethyleneimine Nanostructure Targeted with LPS in a Mouse Model. Iranikhah M, Nazari R, Fasihi-Ramandi M, Taheri RA, Zargar M. Curr Microbiol; 2024 Sep 29; 81(11):383. PubMed ID: 39343859 [Abstract] [Full Text] [Related]
37. Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection. Cassataro J, Estein SM, Pasquevich KA, Velikovsky CA, de la Barrera S, Bowden R, Fossati CA, Giambartolomei GH. Infect Immun; 2005 Dec 29; 73(12):8079-88. PubMed ID: 16299302 [Abstract] [Full Text] [Related]
38. The identification of two protective DNA vaccines from a panel of five plasmid constructs encoding Brucella melitensis 16M genes. Commander NJ, Spencer SA, Wren BW, MacMillan AP. Vaccine; 2007 Jan 02; 25(1):43-54. PubMed ID: 17049676 [Abstract] [Full Text] [Related]